DSIP (Delta Sleep-Inducing Peptide)
DSIP is a naturally occurring neuropeptide first discovered in 1977, named for its ability to induce slow-wave (delta) sleep in animal models. Research suggests it may act as a broad neuromodulator, potentially influencing sleep architecture, stress responses, and pain perception, though its exact mechanisms remain elusive.
01Dosing reference
Amount
100-250 mcg
Frequency
1-3 hours before bed, as needed
Cycle
Often used acutely or cycled (e.g., 5 days on, 2 days off) to prevent tolerance
Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.
02Mechanism of action
01
Neuromodulation
DSIP crosses the blood-brain barrier and interacts with various central nervous system pathways, though a specific 'DSIP receptor' has not been identified.
02
Neurotransmitter Regulation
It appears to modulate the activity of GABAergic, glutamatergic, and other neurotransmitter systems, altering the balance of excitatory and inhibitory signals.
03
Physiological Shift
This modulation may promote the onset of deep, slow-wave sleep, reduce stress-induced metabolic changes, and influence pain pathways.
03Human evidence
Early clinical studies indicated that DSIP administration could improve sleep architecture and reduce insomnia symptoms in some patients.
Based on small, older trials (mostly from the 1980s) with methodological limitations; results were sometimes mixed or inconsistent.
Some research explored the use of DSIP for managing withdrawal symptoms in opiate and alcohol dependence, showing potential for reducing withdrawal severity.
Limited clinical data from older studies; not widely adopted in modern clinical practice.
04Preclinical evidence
Intravenous and intracerebroventricular administration of DSIP in rabbits and rats promoted delta (slow-wave) sleep and altered EEG patterns.
Animal models demonstrated sleep-inducing effects, though responses sometimes varied based on circadian timing and dosage.
DSIP exhibited neuroprotective and stress-protective effects, reducing the physiological impact of acute stress and hypoxia.
Observed in rodent models subjected to various stressors, suggesting a broader adaptogenic role beyond just sleep.
05What is known vs. unknown
Reasonably established
- Originally isolated from the venous blood of rabbits in induced sleep in 1977.
- Known to successfully cross the blood-brain barrier, allowing central nervous system effects.
- Has been studied for multiple potential benefits, including sleep promotion, stress reduction, and pain modulation.
- Often utilized in research settings to investigate the regulation of sleep architecture and circadian rhythms.
Unknowns & limits
- The exact receptor or primary molecular target for DSIP remains unidentified.
- Clinical evidence is largely outdated, lacking large-scale, modern randomized controlled trials to confirm efficacy and safety.
- Optimal dosing protocols and the potential for tolerance with long-term use in humans are not well established.
06Safety & regulatory context
Regulatory statusDSIP is an experimental peptide and is not approved by the FDA for the treatment, diagnosis, or prevention of any medical condition. In research settings, it is generally reported to have low acute toxicity. However, potential side effects observed in anecdotal reports and early studies include headaches, grogginess, or paradoxical sleep disturbances (such as insomnia if dosed incorrectly). Its use is strictly restricted to research and educational purposes, and it is not intended for human consumption outside of approved clinical trials.
07Compared with Epithalon
DSIP (Delta Sleep-Inducing Peptide) vs. Epithalon
Key difference
DSIP is primarily investigated for acute sleep induction and stress modulation, whereas Epithalon is studied for pineal gland regulation, melatonin production, and long-term anti-aging effects.
When researchers discuss each
DSIP is discussed when targeting immediate improvements in sleep architecture and deep sleep onset, while Epithalon is discussed in the context of circadian rhythm restoration and longevity.
08Glossary
Delta Sleep
The deepest phase of non-rapid eye movement (NREM) sleep, characterized by high-amplitude, low-frequency brain waves, crucial for physical recovery.
Neuropeptide
Small protein-like molecules used by neurons to communicate with each other and influence brain activity.
Blood-Brain Barrier
A highly selective semipermeable border that prevents many substances in the circulating blood from crossing into the central nervous system.
09Knowledge check
Q1What phase of sleep is DSIP primarily thought to promote?
Why: DSIP stands for Delta Sleep-Inducing Peptide, named for its observed ability to promote the deep, slow-wave delta phase of sleep.
Q2Which of the following is a major limitation in the clinical understanding of DSIP?
Why: Despite decades of research, the specific receptor that DSIP binds to and its exact mechanism of action in the body are still not fully understood.
Q3Which interpretation of the clinical evidence for DSIP is best supported by the dossier?
Why: The dossier states that early clinical studies (mostly from the 1980s) were small and methodologically limited, with sometimes mixed or inconsistent results, and that clinical evidence is largely outdated and lacks large modern trials.
Q4According to the dossier's comparison with Epithalon, DSIP is primarily discussed by researchers when the goal is to:
Why: The dossier explains that DSIP is discussed when targeting immediate improvements in sleep architecture and deep sleep onset, whereas Epithalon is associated with pineal regulation, melatonin, and long-term anti-aging contexts.
Q5Which statement accurately reflects the safety and regulatory status of DSIP as described in the dossier?
Why: The dossier states DSIP is an experimental peptide not FDA-approved, restricted to research and educational purposes, reported to have low acute toxicity in research contexts, and lists anecdotal/early-study side effects including headaches, grogginess, or paradoxical sleep disturbances.
10Sources
More in Sleep & Recovery
Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.